Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic kidney disease · Advanced solid tumors

Bayer

Bayer AG

Bayer drug portfolio — 62 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

Bayer pipeline

Portfolio lens on 62 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Bayer drug portfolio — 62 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

62 compounds

  1. abiraterone

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in Bayer's portfolio. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Steroid 5-alpha-reductase inhibitor

  2. abiraterone acetate

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.

    Target
    Steroid 17-alpha-hydroxylase/17,20 lyase
    Mechanism
    Cytochrome P450 17A1 inhibitor

  3. administration

    Development asset linked to Bayer in public FDA and regional records.

  4. aflibercept

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Placenta growth factor.

    Target
    Placenta growth factor
    Mechanism
    Placenta growth factor inhibitor

  5. anti-

    Development asset linked to Bayer in public FDA and regional records.

  6. antiplatelet

    Development asset linked to Bayer in public FDA and regional records.

  7. asenapine maleate

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  8. atazanavir

    Antiinfectives for systemic use (J05)

    Antiinfectives for systemic use (J05) compound in Bayer's portfolio.

  9. capsule

    Development asset linked to Bayer in public FDA and regional records.

  10. capsules

    Development asset linked to Bayer in public FDA and regional records.

  11. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  12. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  13. cerivastatin sodium

    US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

    Target
    3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Mechanism
    HMG-CoA reductase inhibitor

  14. chloride

    Development asset linked to Bayer in public FDA and regional records.

  15. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  16. cm310

    Development asset linked to Bayer in public FDA and regional records.

  17. combination

    Development asset linked to Bayer in public FDA and regional records.

  18. control

    Development asset linked to Bayer in public FDA and regional records.

  19. dabigatran

    Development asset linked to Bayer in public FDA and regional records. Molecular target: Prothrombin.

    Target
    Prothrombin
    Mechanism
    Thrombin inhibitor

  20. damoctocog alfa pegol

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in Bayer's portfolio. Molecular target: Coagulation factor VIII.

    Target
    Coagulation factor VIII
    Mechanism
    Coagulation factor VIII exogenous protein

  21. desmopressin acetate

    US regulatory status: approved. Molecular target: Vasopressin receptor.

    Target
    Vasopressin receptor
    Mechanism
    Vasopressin receptor agonist

  22. dose

    Development asset linked to Bayer in public FDA and regional records.

  23. embolic

    Development asset linked to Bayer in public FDA and regional records.

  24. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  25. endocrine

    Development asset linked to Bayer in public FDA and regional records.

  26. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  27. finerenone

    Cardiovascular system (C09)

    US regulatory status: approved. Molecular target: Mineralocorticoid receptor.

    Target
    Mineralocorticoid receptor
    Mechanism
    Mineralocorticoid receptor antagonist

  28. granule

    Development asset linked to Bayer in public FDA and regional records.

  29. granules

    Development asset linked to Bayer in public FDA and regional records.

  30. hydromorphone

    Development asset linked to Bayer in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  31. infusion

    Development asset linked to Bayer in public FDA and regional records.

  32. inhibitor

    Development asset linked to Bayer in public FDA and regional records.

  33. injection

    Development asset linked to Bayer in public FDA and regional records.

  34. itraconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  35. ivermectin

    US regulatory status: approved. Molecular target: Glutamate-gated chloride channel.

    Target
    Glutamate-gated chloride channel
    Mechanism
    Glutamate-gated chloride channel modulator

  36. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  37. larotrectinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Bayer's portfolio. Molecular target: Neurotrophic tyrosine kinase receptor.

    Target
    Neurotrophic tyrosine kinase receptor
    Mechanism
    Neurotrophic tyrosine kinase receptor inhibitor

  38. malignant

    Development asset linked to Bayer in public FDA and regional records.

  39. metformin

    Development asset linked to Bayer in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.

    Mechanism
    Mitochondrial complex I (NADH dehydrogenase) inhibitor

  40. nitroglycerin

    US regulatory status: approved. Molecular target: Soluble guanylate cyclase.

    Target
    Soluble guanylate cyclase
    Mechanism
    Soluble guanylate cyclase activator

  41. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  42. pemetrexed

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  43. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  44. phentermine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter releasing agent

  45. placebo

    Development asset linked to Bayer in public FDA and regional records.

  46. powder

    Development asset linked to Bayer in public FDA and regional records.

  47. praziquantel

    US regulatory status: approved. Molecular target: Voltage-activated calcium channel beta 1 subunit.

    Target
    Voltage-activated calcium channel beta 1 subunit
    Mechanism
    Voltage-activated calcium channel beta 1 subunit blocker

  48. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  49. radium ra223 dichloride

    Various (V10)

    Various (V10) compound in Bayer's portfolio. Mechanism: Radiotherapy agent.

    Mechanism
    Radiotherapy agent

  50. riociguat

    Cardiovascular system (C02)

    US regulatory status: approved. Molecular target: Soluble guanylate cyclase.

    Target
    Soluble guanylate cyclase
    Mechanism
    Soluble guanylate cyclase positive allosteric modulator

  51. rosuvastatin

    Development asset linked to Bayer in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  52. sildenafil

    Genito-urinary system and sex hormones (G04)

    Genito-urinary system and sex hormones (G04) compound in Bayer's portfolio. Mechanism: Phosphodiesterase 5A inhibitor.

    Mechanism
    Phosphodiesterase 5A inhibitor

  53. solution

    Development asset linked to Bayer in public FDA and regional records.

  54. solvent

    Development asset linked to Bayer in public FDA and regional records.

  55. sotorasib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: GTPase KRas.

    Target
    GTPase KRas
    Mechanism
    GTPase KRas inhibitor

  56. statin

    Development asset linked to Bayer in public FDA and regional records.

  57. stro-

    Development asset linked to Bayer in public FDA and regional records.

  58. tablet

    Development asset linked to Bayer in public FDA and regional records.

  59. tablets

    Development asset linked to Bayer in public FDA and regional records.

  60. therapy

    Development asset linked to Bayer in public FDA and regional records.

  61. treatment

    Development asset linked to Bayer in public FDA and regional records.

  62. vericiguat

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Soluble guanylate cyclase.

    Target
    Soluble guanylate cyclase
    Mechanism
    Soluble guanylate cyclase activator

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.